Hay fever vaccine specialist Allergy Therapeutics PLC (LON:AGY) has published new data highlighting the effectiveness of its technology as an adjuvant compared to existing treatment.
An adjuvant stimulates the body’s immune response to an antigen and helps it react quicker to the threat.
WATCH: 'Pivotal' year ahead for Allergy Therapeutics with key trial readouts
The study highlighted Allergy’s microcrystalline tyrosine (MCT) was a suitable and flexible alternative to aluminium hydroxide in both allergen-specific immunotherapy and infectious disease applications.
"These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response." said Matthias Kramer, Allergy Therapeutics' International Medical Director and co-author of the paper.
"We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines."
Studies in a cancer (melanoma) model are underway.
Allergy published the findings of its work online in the Journal of Immunology.